Community Trust & Investment Co. Lowers Position in Zoetis Inc. $ZTS

Community Trust & Investment Co. trimmed its position in shares of Zoetis Inc. (NYSE:ZTS) by 25.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 86,550 shares of the company’s stock after selling 29,858 shares during the quarter. Community Trust & Investment Co.’s holdings in Zoetis were worth $10,890,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Halbert Hargrove Global Advisors LLC boosted its holdings in Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares in the last quarter. Global Wealth Strategies & Associates acquired a new position in Zoetis during the 4th quarter worth approximately $25,000. KERR FINANCIAL PLANNING Corp purchased a new position in shares of Zoetis during the 3rd quarter worth approximately $31,000. Holos Integrated Wealth LLC purchased a new position in shares of Zoetis during the 4th quarter worth approximately $32,000. Finally, Board of the Pension Protection Fund acquired a new stake in shares of Zoetis in the 4th quarter valued at approximately $38,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

ZTS opened at $115.31 on Tuesday. Zoetis Inc. has a 1-year low of $114.36 and a 1-year high of $172.23. The stock has a market cap of $48.68 billion, a P/E ratio of 19.15, a P/E/G ratio of 1.77 and a beta of 0.95. The stock’s 50 day simple moving average is $124.15 and its 200 day simple moving average is $130.02. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis’s revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s payout ratio is 35.22%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. Leerink Partners restated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Morgan Stanley set a $160.00 target price on Zoetis in a report on Thursday, December 18th. Weiss Ratings upgraded shares of Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, March 12th. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Finally, Barclays started coverage on shares of Zoetis in a report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price target for the company. Six investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Zoetis currently has an average rating of “Hold” and a consensus target price of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.